The influence of religious activity and polygenic schizophrenia risk on religious delusions in schizophrenia.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
08 2019
Historique:
received: 24 08 2018
revised: 28 11 2018
accepted: 16 12 2018
pubmed: 7 1 2019
medline: 29 9 2020
entrez: 7 1 2019
Statut: ppublish

Résumé

Religious delusions are a common symptom in patients experiencing psychosis, with varying prevalence rates of religious delusions across cultures and societies. To enhance our knowledge of this distinct psychotic feature, we investigated the mutually-adjusted association of genetic and environmental factors with occurrence of religious delusions. We studied 262 adult German patients with schizophrenia or schizoaffective disorder. Association with lifetime occurrence of religious delusions was tested by multiple logistic regression for the following putative predictors: self-reported degree of religious activity, DSM-IV diagnosis, sex, age, education level, marital status, presence of acute delusion at the time of interview and an individual polygenic schizophrenia-risk score (SZ-PRS, available in 239 subjects). Of the 262 patients, 101 (39%) had experienced religious delusions. The risk of experiencing religious delusions was significantly increased in patients with strong religious activity compared to patients without religious affiliation (OR = 3.6, p = 0.010). Low or moderate religious activity had no significant effect. The same analysis including the SZ-PRS confirmed the effect of high religious activity on occurrence of religious delusions (OR = 4.1, p = 0.008). Additionally, the risk of experiencing religious delusions increased with higher SZ-PRS (OR 1.4, p = 0.020, using pT = 0.05 for SZ-PRS calculation). None of the other variables were significantly associated with lifetime occurrence of religious delusions. Our results suggest that strong religious activity and high SZ-PRS are independent risk factors for the occurrence of religious delusions in schizophrenia and schizoaffective disorder.

Sections du résumé

BACKGROUND
Religious delusions are a common symptom in patients experiencing psychosis, with varying prevalence rates of religious delusions across cultures and societies. To enhance our knowledge of this distinct psychotic feature, we investigated the mutually-adjusted association of genetic and environmental factors with occurrence of religious delusions.
METHODS
We studied 262 adult German patients with schizophrenia or schizoaffective disorder. Association with lifetime occurrence of religious delusions was tested by multiple logistic regression for the following putative predictors: self-reported degree of religious activity, DSM-IV diagnosis, sex, age, education level, marital status, presence of acute delusion at the time of interview and an individual polygenic schizophrenia-risk score (SZ-PRS, available in 239 subjects).
RESULTS
Of the 262 patients, 101 (39%) had experienced religious delusions. The risk of experiencing religious delusions was significantly increased in patients with strong religious activity compared to patients without religious affiliation (OR = 3.6, p = 0.010). Low or moderate religious activity had no significant effect. The same analysis including the SZ-PRS confirmed the effect of high religious activity on occurrence of religious delusions (OR = 4.1, p = 0.008). Additionally, the risk of experiencing religious delusions increased with higher SZ-PRS (OR 1.4, p = 0.020, using pT = 0.05 for SZ-PRS calculation). None of the other variables were significantly associated with lifetime occurrence of religious delusions.
CONCLUSIONS
Our results suggest that strong religious activity and high SZ-PRS are independent risk factors for the occurrence of religious delusions in schizophrenia and schizoaffective disorder.

Identifiants

pubmed: 30611655
pii: S0920-9964(18)30721-7
doi: 10.1016/j.schres.2018.12.025
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

255-261

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Heike Anderson-Schmidt (H)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen 37075, Germany. Electronic address: heike.anderson-schmidt@med.uni-goettingen.de.

Katrin Gade (K)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen 37075, Germany.

Dörthe Malzahn (D)

Department of Genetic Epidemiology, University Medical Center Göttingen, Georg-August-University, Göttingen 37099, Germany.

Sergi Papiol (S)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.

Monika Budde (M)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany.

Urs Heilbronner (U)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany.

Daniela Reich-Erkelenz (D)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany.

Kristina Adorjan (K)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.

Janos L Kalman (JL)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany; International Max Planck Research School for Translational Psychiatry, Max Planck Institute of Psychiatry, Munich 80804, Germany.

Fanny Senner (F)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.

Ashley L Comes (AL)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany; International Max Planck Research School for Translational Psychiatry, Max Planck Institute of Psychiatry, Munich 80804, Germany.

Laura Flatau (L)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany.

Anna Gryaznova (A)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany.

Maria Hake (M)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany.

Markus Reitt (M)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen 37075, Germany.

Max Schmauß (M)

Department of Psychiatry and Psychotherapy, Bezirkskrankenhaus Augsburg, Augsburg 86156, Germany.

Georg Juckel (G)

Department of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum 44791, Germany.

Jens Reimer (J)

Department of Psychiatry, Klinikum Bremen-Ost, Bremen 28325, Germany.

Jörg Zimmermann (J)

Department of Psychiatry, Klinikum Bremen-Ost, Bremen 28325, Germany; Karl-Jaspers Clinic, European Medical School Oldenburg-Groningen, Oldenburg 26160, Germany.

Christian Figge (C)

Karl-Jaspers Clinic, European Medical School Oldenburg-Groningen, Oldenburg 26160, Germany.

Eva Reininghaus (E)

Department of Psychiatry and Psychotherapeutic Medicine, Research Unit for Bipolar Affective Disorder, Medical University of Graz, Graz 8036, Austria.

Ion-George Anghelescu (IG)

Department of Psychiatry, Dr. Fontheim - Mental Health, Liebenburg 38704, Germany.

Carsten Konrad (C)

Department of Psychiatry and Psychotherapy, Agaplesion Diakonieklinikum, Rotenburg 27356, Germany.

Andreas Thiel (A)

Department of Psychiatry and Psychotherapy, Agaplesion Diakonieklinikum, Rotenburg 27356, Germany.

Martin von Hagen (M)

Clinic for Psychiatry and Psychotherapy, Clinical Center Werra-Meißner, Eschwege 37269, Germany.

Manfred Koller (M)

Asklepios Specialized Hospital, Göttingen 37081, Germany.

Sebastian Stierl (S)

Psychiatric Hospital Lüneburg, Lüneburg 21339, Germany.

Harald Scherk (H)

AMEOS Clinical Center Osnabrück, Osnabrück 49088, Germany.

Carsten Spitzer (C)

ASKLEPIOS Specialized Hospital Tiefenbrunn, Rosdorf 37124, Germany.

Here Folkerts (H)

Department of Psychiatry, Psychotherapy and Psychosomatics, Clinical Center Wilhelmshaven, Wilhelmshaven 26389, Germany.

Thomas Becker (T)

Department of Psychiatry II, Ulm University, Bezirkskrankenhaus Günzburg, Günzburg 89312, Germany.

Detlef E Dietrich (DE)

AMEOS Clinical Center Hildesheim, Hildesheim 31135, Germany; Center for Systems Neuroscience (ZSN), Hannover 30559, Germany.

Till F M Andlauer (TFM)

Department of Translational Psychiatry, Max Planck Institute of Psychiatry, Munich 80804, Germany.

Franziska Degenhardt (F)

Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Bonn 53127, Germany; Department of Genomics, Life & Brain Center, University of Bonn, Bonn 53127, Germany.

Markus M Nöthen (MM)

Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Bonn 53127, Germany; Department of Genomics, Life & Brain Center, University of Bonn, Bonn 53127, Germany.

Stephanie H Witt (SH)

Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim 68159, Germany.

Marcella Rietschel (M)

Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim 68159, Germany.

Jens Wiltfang (J)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen 37075, Germany; German Center for Neurodegenerative Diseases (DZNE), Göttingen 37075, Germany; iBiMED, Medical Sciences Department, University of Aveiro, Aveiro, Portugal.

Peter Falkai (P)

Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.

Thomas G Schulze (TG)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen 37075, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH